Development of peptide antagonists that target estrogen receptor-cofactor interactions

被引：35

作者：

McDonnell, DP ^{[1
]}

Chang, CY ^{[1
]}

Norris, JD ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2000年 / 74卷 / 05期

关键词：

peptide antagonists; estrogen; receptor-cofactor interaction; transcriptional activity;

D O I：

10.1016/S0960-0760(00)00109-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have developed a series of high-affinity peptide antagonists that inhibit the transcriptional activity of both subtypes of the human estrogen receptor (ER alpha and ER beta). We believe that it will be possible to develop these peptides, or corresponding peptidomimetic derivatives, into pharmaceuticals for use in the treatment of breast cancer and other estrogenopathies. It is anticipated that drugs of this type could be used in combination with classical antiestrogens, such as tamoxifen, to achieve a complete blockage of ER-transcriptional activity. Although ER has been the primary target of our studies to date, it is likely that the insights gained from this work will apply to other nuclear receptors and transcription factors. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：327 / 335

页数：9

共 47 条

[1]

ALLAN GF, 1992, J BIOL CHEM, V267, P19513

[2] Estrogen activity and novel tissue selectivity of Δ8,9-dehydroestrone sulfate in postmenopausal women [J].

Baracat, E ;

Haidar, R ;

López, FJ ;

Pickar, J ;

Dey, M ;

Negro-Vilar, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (06) :2020-2027

[3] Molecular basis of agonism and antagonism in the oestrogen receptor [J].

Brzozowski, AM ;

Pike, ACW ;

Dauter, Z ;

Hubbard, RE ;

Bonn, T ;

Engstrom, O ;

Ohman, L ;

Greene, GL ;

Gustafsson, JA ;

Carlquist, M .

NATURE, 1997, 389 (6652) :753-758

[4]

Chang CY, 1999, MOL CELL BIOL, V19, P8226

[5] A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS [J].

CHEN, JD ;

EVANS, RM .

NATURE, 1995, 377 (6548) :454-457

[6]

Clark JH, 1979, MONOGRAPHS ENDOCRINO

[7] The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].

Cummings, SR ;

Eckert, S ;

Krueger, KA ;

Grady, D ;

Powles, TJ ;

Cauley, JA ;

Norton, L ;

Nickelsen, T ;

Bjarnason, NH ;

Morrow, M ;

Lippman, ME ;

Black, D ;

Glusman, JE ;

Costa, A ;

Jordan, VC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197

[8] Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-β receptor and possess cellular activity [J].

Eaton, SR ;

Cody, WL ;

Doherty, AM ;

Holland, DR ;

Panek, RL ;

Lu, GH ;

Dahring, TK ;

Rose, DR .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (22) :4329-4342

[9] A signature motif in transcriptional co-activators mediates binding to nuclear receptor [J].

Heery, DM ;

Kalkhoven, E ;

Hoare, S ;

Parker, MG .

NATURE, 1997, 387 (6634) :733-736

[10]

HENDERSON IC, 1996, TAMOXIFEN GUIDE CLIN, P41

← 1 2 3 4 5 →